Carotuximab

Drug Profile

Carotuximab

Alternative Names: Chimeric Antibody (TRC105) to CD105; DE 122; NSC#754227; TRC-105

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roswell Park Cancer Institute
  • Developer National Cancer Institute (USA); Santen Pharmaceutical; TRACON Pharmaceuticals; University of Alabama at Birmingham; University of Minnesota
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; ENG protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemangiosarcoma
  • Phase II Choriocarcinoma; Glioblastoma; Hepatocellular carcinoma; Renal cell carcinoma; Soft tissue sarcoma; Wet age-related macular degeneration
  • Phase I/II Breast cancer
  • Phase I Non-small cell lung cancer
  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Colorectal cancer
  • Discontinued Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer

Most Recent Events

  • 07 Sep 2017 TRACON completes enrolment in phase II part of the phase I/II TRAXAR trial for Renal cell carcinoma (combination therapy, late-stage disease, second-line therapy or greater) in USA, Hungary, Czech Republic and United Kingdom (NCT01806064)
  • 21 Aug 2017 Efficacy data from a phase I/II trial in Hepatocellular carcinoma released by TRACON Pharmaceuticals
  • 08 Aug 2017 National Cancer Institute completes a phase-II trial in Renal cell carcinoma (combination therapy, late-stage disease, second-line therapy or greater, metastatic disease) in Taiwan, Australia, USA (IV) (NCT01727089)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top